RM Bio‑Tech Secures CDE Approval for HF001 Stem‑Cell Therapy in Type 2 Diabetes
Beijing RM Bio‑Tech Co., Ltd. announced that the Center for Drug Evaluation (CDE) under the...
Diabetes
Pfizer to Acquire Metsera for $4.9 B, Expanding Its Obesity & Cardiometabolic Pipeline
Pfizer Inc. (NYSE: PFE) announced today that it will acquire Metsera, Inc. (NASDAQ: MTSR), a...
Innovent Secures 2nd NMPA Approval for Mazdutide – First Dual GLP‑1/GCGR Therapy for Type 2 Diabetes
Innovent Biologics Ltd. (HKG: 1801) announced that its mazdutide injection (IBI362) has received its second...
Eli Lilly’s Orforglipron Outperforms Oral Semaglutide in ACHIEVE‑3 Phase 3 Trial
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the open‑label, randomized Phase 3...
Eli Lilly’s Mounjaro Shows Promising Results in Children with Type 2 Diabetes
A recent clinical study published by Eli Lilly & Co. (NYSE: LLY) demonstrates that the GLP‑1...
Novo Nordisk Rybelsus Gains Cardio Benefit from SOUL Trial
Novo Nordisk A/S (NYSE: NVO) announced that the European Medicines Agency (EMA)’s Committee for Medicinal Products...
Remedium Bio Teams Up With Eli Lilly to Push Gene‑Therapy Frontiers for Diabetes and Obesity
Remedium Bio, Inc. (Remedium) announced a multi‑target R&D partnership with Eli Lilly & Co. (NYSE: LLY) to...
Sihuan Pharma Secures IND for Dual‑Target GLP‑1/GCGR Drug P052 Injection
China‑based Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced that the Investigational New Drug (IND)...
FDA Launches “Green List” to Shield U.S. Markets from Unsafe GLP‑1 APIs
The U.S. Food and Drug Administration (FDA) today announced a new “green list” import alert...
Replicate Bioscience Teams With Novo Nordisk On srRNA‑Powered Metabolic Drugs
Replicate Bioscience, a pioneer in self‑replicating RNA (srRNA) therapeutics, announced a landmark multi‑year research partnership...
Sanofi’s Tzield Earns China NMPA Approval for Stage 2 Type 1 Diabetes
French pharmaceutical giant Sanofi (NASDAQ: SNY) today announced that its investigational drug Tzield (teplizumab) has...
Eli Lilly & JD Health Form Digital Care Alliance for Obesity, Diabetes, and Alopecia
Eli Lilly (NYSE: LLY) China has announced a strategic partnership with JD Health (HKG: 6618)...
GoodRx and Novo Nordisk Introduce $499 Monthly Pricing for Semaglutide Pens
Goodrx Holdings Inc (NASDAQ: GDRX), the leading platform for medication savings in the U.S., has...
Eli Lilly Hikes Mounjaro Price in UK by 170% for Private-Pay Patients
US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) announced on August 14, 2025, that...
HighTide Therapeutics Collaborates with IMB to Assess HTD1801 in T2DM with CKD
China-based HighTide Therapeutics, Inc. (HKG: 2511) announced the commencement of a collaborative project with the...
Guangzhou Innogen Pharmaceuticals Launches H-Share Global Offering in Hong Kong
China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd. (HKG: 2591) officially launched its H-share global offering...
CSPC Pharmaceutical’s Semaglutide Injection NMPA Marketing Application Accepted
China-based CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the marketing application for its semaglutide...
Innovent Biologics’ IBI3032 Receives IND Approval From FDA and NMPA for GLP-1RA Clinical Trials
China-based Innovent Biologics (HKG: 1801) announced that its self-developed oral small molecule GLP-1 receptor agonist...
Innovent Biologics’ Mazdutide Gets NMPA Nod for Weight Management
China’s National Medical Products Administration (NMPA) has approved Innovent Biologics, Inc.’s (HKG: 1801) mazdutide (IBI362),...
Gan & Lee Pharmaceuticals Presents Phase II Results of GZR18 and GZR4 at ADA Scientific Sessions
China-based Gan & Lee Pharmaceuticals (SHA: 603087) presented multiple Phase II clinical outcomes for its...